| 24/05 | Knight Therapeutics Inks Agreements with Rigel Pharmaceuticals to Commercialize Fostama.. |  |
| 24/05 | KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive License and Supply Agreements with Rigel.. | |
| 24/05 | Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Phar.. | |
| 24/05 | Knight Therapeutics Enters into Exclusive License and Supply Agreements with Rigel Phar.. | |
| 12/05 | Knight Therapeutics Reports Q1 Loss Per Share $0.16, Updates Revenue Guidance | |
| 12/05 | TRANSCRIPT : Knight Therapeutics Inc., Q1 2022 Earnings Call, May 12, 2022 | |
| 12/05 | Knight Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31,.. | |
| 12/05 | Knight Therapeutics Reports First Quarter 2022 Results | |
| 12/05 | Knight Therapeutics Reports First Quarter 2022 Results | |
| 12/05 | Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal Year 2022 | |
| 12/05 | Knight Therapeutics and Helsinn Healthcare SA Enters into Exclusive License, Distributi.. | |
| 12/05 | Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio.. | |
| 12/05 | Knight Therapeutics and Helsinn Healthcare SA Enter into Exclusive License, Distributio.. | |
| 12/05 | Knight to Present at the 2022 RBC Capital Markets Global Healthcare Conference in New Y.. | |
| 12/05 | Knight Therapeutics Inc. announces voting results from the Annual Meeting | |
| 12/05 | Knight Therapeutics Inc. announces voting results from the Annual Meeting | |
| 11/05 | TRANSCRIPT : Knight Therapeutics Inc. - Shareholder/Analyst Call | |
| 05/05 | Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call | |
| 05/05 | Notice of Knight Therapeutics' First Quarter 2022 Results Conference Call | |
| 26/04 | Knight to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference | |
| 30/03 | Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and Licens.. | |
| 29/03 | Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million, License a.. | |
| 25/03 | Knight Therapeutics Inc. places on The Globe and Mail's third-annual Women Lead Here be.. | |
| 24/03 | TRANSCRIPT : Knight Therapeutics Inc., Q4 2021 Earnings Call, Mar 24, 2022 | |
| 24/03 | Knight Therapeutics Swings to a Fourth-Quarter Loss on Non-Cash Charges | |
| 24/03 | Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, .. | |
| 24/03 | Knight Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, .. | |
| 24/03 | KNIGHT THERAPEUTICS BRIEF : For fiscal 2022, Knight Expects to Generate $260 to $265 milli.. | |
| 24/03 | KNIGHT THERAPEUTICS BRIEF : Reports Q4 Net Loss $8,3 Million Vs Income of Near 8.233 Milli.. | |
| 24/03 | Knight Therapeutics Reports Fourth Quarter and Year-End 2021 Results and Provides 2022 .. | |
| 24/03 | Knight Therapeutics Inc. Reports Earnings Results for the Fourth Quarter Ended December.. | |
| 24/03 | Knight Therapeutics Inc. Provides Revenue Guidance for the Fiscal 2022 | |
| 24/03 | NORTH AMERICAN MORNING BRIEFING : Stock Futures -3- | |
| 17/03 | Notice of Knight Therapeutics' Fourth Quarter and Year End 2021 Results Conference Call | |
| 06/01 | Knight Therapeutics Announces Approval of Breast Cancer Drug, Halaven, in Colombia | |
| 06/01 | KNIGHT THERAPEUTICS BRIEF : Announces Approval of Halaven in Colombia | |
| 06/01 | Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia | |
| 06/01 | Knight Therapeutics Inc. anuncia la aprobación de Halaven® en Colombia |  |
| 06/01 | Knight Therapeutics Inc. Announces Approval of Halaven® in Colombia | |
| 05/01 | Knight Therapeutics Inc. Announces Approval of Lenvima in Colombia | |
| 04/01 | Knight Therapeutics Reports Approval of Lenvima in Colombia | |
| 04/01 | Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia | |
| 04/01 | Knight Therapeutics Inc. Announces Approval of Lenvima® in Colombia | |
| 2021 | Knight to Present at Stifel GMP's The Future of Healthcare Conference | |
| 2021 | Knight to Present at Stifel GMP's The Future of Healthcare Conference | |
| 2021 | Knight Therapeutics Reports Q3 Basic Net Loss $0.07 | |
| 2021 | TRANSCRIPT : Knight Therapeutics Inc., Q3 2021 Earnings Call, Nov 11, 2021 | |
| 2021 | Knight Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months.. | |
| 2021 | Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 12, .. | |
| 2021 | Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, .. | |
| 2021 | Knight Therapeutics Reports Third Quarter 2021 | |
| 2021 | Notice of Knight Therapeutics Third Quarter 2021 Results Conference Call | |
| 2021 | Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call | |
| 2021 | Notice of Knight Therapeutics' Third Quarter 2021 Results Conference Call | |
| 2021 | INCYTE : Signs Supply, Distribution Deal for Tafasitamab, Pemigatinib in Latin America | |
| 2021 | KNIGHT THERAPEUTICS : in Supply and Distribution Agreement with NASDAQ's Incyte for Tafasi.. | |
| 2021 | KNIGHT THERAPEUTICS BRIEF : Enters into Exclusive Supply and Distribution Agreement with N.. | |
| 2021 | INCYTE : Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with .. | |
| 2021 | Knight Therapeutics Inc. Enters into Exclusive Supply and Distribution Agreement with I.. | |
| 2021 | KNIGHT THERAPEUTICS : Reports Second Quarter 2021 | |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Weak Chinese -3- | |
| 2021 | TRANSCRIPT : Knight Therapeutics Inc., Q2 2021 Earnings Call, Aug 13, 2021 | |
| 2021 | KNIGHT THERAPEUTICS : Posts Q2 EPS of C$0.23; Revenue Reaches Record C$65.8 Million | |
| 2021 | Tranche Update on Knight Therapeutics Inc.'s Equity Buyback Plan announced on July 10, .. | |
| 2021 | KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Posts Q2 EPS Basic C$0.2.. | |
| 2021 | KNIGHT THERAPEUTICS : Earnings Flash (GUD.TO) KNIGHT THERAPEUTICS Reports Q2 Revenue C$65... | |
| 2021 | NORTH AMERICAN MORNING BRIEFING : Blockbuster -3- | |
| 2021 | Notice of Knight Therapeutics' Second Quarter 2021 Results Conference Call | |
| 2021 | Knight Therapeutics Inc.'s Equity Buyback announced on July 10, 2020, has expired with .. | |
| 2021 | UPDATE : Knight Therapeutics Up 3% as Launches Normal Course Issuer Bid | |
| 2021 | KNIGHT THERAPEUTICS : Launches Normal Course Issuer Bid | |
| 2021 | Knight Therapeutics Inc. announces an Equity Buyback for 10,267,956 shares, representin.. | |
| 2021 | KNIGHT THERAPEUTICS : Announces Normal Course Issuer Bid | |
| 2021 | Knight Therapeutics Inc. authorizes a Buyback Plan. | |
| 2021 | Knight Therapeutics Gets Health Canada Approval for Neratinib | |
English (USA)
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Italiano
Nederlands (Nederland)
Nederlands (België)
bourse
Rapport
